Clinical Trial Update: Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study [Phase 3]

View source ↗

Summary

Phase 3 safety extension study enrolling by invitation for subjects with HR-positive, HER2-negative breast cancer who completed the OVELIA study. Sponsor Tolmar…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Snippet

Sponsor: Tolmar Inc. | Conditions: Breast Cancer | Phase 3 | Status: ENROLLING_BY_INVITATION